Senators work to Reform FDA’s Medical Device Inspection Process with Bipartisan Bill

February 27, 2017

On Wednesday, February 15th, Senators Michael Bennet (D – CO) and Johnny Isakson (R – GA) introduced a bill to improve FDA’s medical device inspection process.  If passed, the bill would amend the Federal Food, Drug, and Cosmetic (FD&C) Act, to establish “a risk-based inspections process to ensure the frequency and nature of inspections are more consistent around the world, states the press release from Senator Bennet.

Additionally, Mark Brager, President and CEO of Advanced Medical Technology Association (AdvaMed), notes that “the legislation would also:

  • Establish a process for companies to address deficiencies more quickly and robustly;
  • Create a more focused and efficient inspection process for FDA;
  • Harmonize the inspection process to eliminate regional variations; and
  • Improve communications between FDA and companies to ensure timely implementation of any remediation plans.”

According to Mr. Brager’s statement, “both the medical technology industry and FDA recognize the need for a robust inspections process to help ensure the continued availability of safe and effective devices and diagnostics for patients.” However, due to a lack of consistency, predictability and transparency, FDA’s current inspection process is simply not getting the job done.

In a recent statement, Senator Isakson noted that “the current device facility inspection process lacks transparency, predictability and consistency between facilities.” Furthermore, he explained that “this bill is designed to improve communication and consistency in the device facility inspections process, which will allow both FDA and device manufacturers to make more efficient use of resources.”

If passed, this bill would allow FDA to use its resources in a more efficient manner and ensure patient safety when using medical devices.  It will be very interesting to watch as this bill makes its way through the legislative system.  We will provide updates as they become available.

Do you manufacture a medical device or any other type of FDA-regulated product? As the process changes, we can help ensure that your product will pass all of FDA’s inspections. For additional information on our services and how we can help you, contact us today.

TAGS:

September 13, 2018

FDA Releases Draft Guidance on Benefit-Risk Determinations for Devices

On Thursday, September 6th, the FDA released a new draft guidance regarding benefit-risk determinations in medical device premarket approval applications (PMAs), De Novo requests, and humanitarian...

November 24, 2015

Formal Meetings with the FDA Regarding Biosimilars: What’s Changed?

Recently, biosimilars have made a definite appearance on the FDA’s radar, an expected result after the first biosimilar product gained FDA approval in March and the FDA’s release of four final...

March 15, 2019

FDA Announces Update to Nonproprietary Naming Convention for Biosimilar Products

On Thursday, March 7th, FDA published a revised draft guidance, updating its nonproprietary naming convention for biological products licensed under section 351 of the Public Health Service Act (PHS...